GSK plc American (GSK) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
GSK plc American (GSK) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How GSK Turns Every Dollar of Sales Into Real Bottom-Line Profit
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring GSK)
- ✓Live walkthrough of GSK's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
GSK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GSK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GSK. Explore sector supply chains on /butterfly.
GSK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is GSK plc American (GSK)?
In Trailing 12 Months, GSK converted $13.8B of revenue into a 41% gross margin, 13.9% operating margin, and $2.2B in free cash flow (15.8% FCF margin).